Climb Bio, Inc.
CLYMNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $802.66M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.64$18.33
- Volume (live)
- -
- Avg. volume (3M)
- 1.30M
Climb Bio (CLYM) Stock Price & Financial Analysis
Climb Bio Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.44 - $11.23 |
|---|---|
| 52-Week High | $18.33 |
| 52-Week Low | $1.64 |
| Open | $10.57 |
| Volume (last close) | 654.06K |
| Average Volume (3M) | 1.30M |
| 50-Day MA | $13.56 |
|---|---|
| 200-Day MA | $10.15 |
| 1-Year Change | +429.65% |
| Market Cap | 802.66M |
|---|---|
| Shares Outstanding | 76.15M |
| Price to Book (P/B) | 3.35 |
| EV/EBITDA | -12.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Climb Bio at a Glance
As of the Oct 22, 2026 close, Climb Bio (CLYM) has a market capitalization of $802.66M.
As of its latest reported balance sheet, it holds $44.11M in cash and securities against $1.31M of debt, a net cash position of $42.79M.
Climb Bio does not currently pay a dividend.
The share price is up 429.6% over the past year. At $10.54 (the Oct 22, 2026 close) it sits within its 52-week range of $1.64 to $18.33, above its 200-day moving average of $10.15.
Based on 11 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $28.11, 166.7% above the Oct 22, 2026 close.
Frequently Asked Questions About Climb Bio
What is the current stock price for CLYM?
As of the Oct 22, 2026 close, CLYM stock trades at $10.54. The 52-week range is $1.64–$18.33, with a day range of $10.44–$11.23.
What is the P/E ratio for CLYM?
The P/E ratio (Price-to-Earnings) for CLYM is shown in the Key Statistics section. This valuation metric helps compare Climb Bio, Inc. to industry peers.
Does CLYM pay dividends?
Climb Bio does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CLYM?
Based on ratings from 11 professional analysts over the last 90 days, the consensus for CLYM is Buy. The average 12-month price target is $28.11, a 166.7% upside from the Oct 22, 2026 close of $10.54.
What is the market cap of CLYM?
As of the Oct 22, 2026 close, Climb Bio's market capitalization is $802.7M, classifying it as a small-cap company. Climb Bio operates in the Healthcare sector within the Biotechnology industry.